Press release

Interim Report 1 January - 31 March 2010

· A directed new share issue that raised SEK 150 million for the company before transaction costs was implemented in February.

· In March BioInvent entered into a product partnership with Human Genome Sciences to develop and commercialise therapeutic antibodies.

· A phase I study of the BI-505 product candidate for the treatment of multiple myeloma was launched at the beginning of the year.

· Net revenues for January - March 2010: SEK 15.1 million (36,8 including BioInvent's share, SEK 21.7 million, of the first milestone payment for TB-403).

· Current investments together with cash and bank as of 31 March 2010: SEK 179.1 million (192.3).

· Cash flow from current operations and investment activities for January - March 2010: SEK -49.3 million (-20.1).

· Loss after tax for January - March 2010 amounted to SEK -37.9 million (-34.7) and the profit after tax per share was SEK -0.65 (-0.62).

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer and atherosclerosis.

Comments by the CEO
The new share issue carried out in February has put us in a stronger position to be able to further develop our project portfolio and exploit the commercial opportunities that our portfolio and our technology platform represent.

Our agreement with Human Genome Sciences demonstrates our goal of broadening our product portfolio to include new drug candidates. This partnership will initially focus on inflammatory diseases and is an example of how collaboration can pave the way for broadening our participation in a number of innovative new drug concepts. As we establish strong alliances with other companies, we are also continuing to forge ties with academic teams with projects and technology that can result in new drug projects. Within the framework for these types of partnerships we have recently started projects based on interesting mechanisms within cancer and diabetes.

Now that BI-505 has entered into the clinical development phase, we have four clinical projects. Both the product concept itself and our in-house developed screening technology that led to the discovery of the product candidate have attracted a lot of interest recently.

We ended last year by stepping up efforts to develop our own drug portfolio. This year we intend to take additional steps with a view to strengthening the portfolio and the company's profile as a strong organisation in the development of antibody-based drugs. These ambitions combined with the fact that we expect to reach milestones in the form of reporting clinical results and starting new phase ll studies makes me optimistic about 2010.

Lund, Svein Mathisen

Contact
Any questions regarding this report will be answered by:

BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.